Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for Anhedonia and Psychomotor Slowing in Depressed People With HIV
NCT05849038Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Dec 2023
- Primary completion
- Nov 2027
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) and anhedonia ((none)) comparing Baricitinib with Placebo (2 arms). Primary endpoint: Change in corticostriatal functional connectivity (FC) in reward circuit at 10 weeks. Started Dec 2023; status: recruiting.
02
Drugs
baricitinib
03
Conditions
major depressive disorder (MDD)anhedonia ((none))
Beyond the preview
Go deeper on NCT05849038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849038.